By Karen Blum
CHICAGO—Biosimilars for oncology are gaining ground, with more payors implementing strategies to cover them and large projected savings for health plans, health systems and patients, speakers said during a panel discussion at the AMCP 2022 annual meeting.
APRIL 1, 2022